Fidelity-oriented fluorescence imaging probes for beta-galactosidase: From accurate diagnosis to precise treatment.

Bin Feng, Feiyi Chu, Anyao Bi, Xueyan Huang, Yanpeng Fang, Meihui Liu, Fei Chen, Yanbing Li, Wenbin Zeng

Biotechnology advances 2023 Nov

filter terms:

Beta-galactosidase (β-gal), a typical glycosidase catalyzing the hydrolysis of glycosidic bonds, is regarded as a vital biomarker for cell senescence and cancer occurrence. Given the advantages of high spatiotemporal resolution, high sensitivity, non-invasiveness, and being free of ionizing radiations, fluorescent imaging technology provides an excellent choice for in vivo imaging of β-gal. In this review, we detail the representative biotech advances of fluorescence imaging probes for β-gal bearing diverse fidelity-oriented improvements to elucidate their future potential in preclinical research and clinical application. Next, we propose the comprehensive design strategies of imaging probes for β-gal with respect of high fidelity. Considering the systematic implementation approaches, a range of high-fidelity imaging-guided theragnostic are adopted for the individual β-gal-associated biological scenarios. Finally, current challenges and future trends are proposed to promote the next development of imaging agents for individual and specific application scenarios. Copyright © 2023 Elsevier Inc. All rights reserved.

Citation

Bin Feng, Feiyi Chu, Anyao Bi, Xueyan Huang, Yanpeng Fang, Meihui Liu, Fei Chen, Yanbing Li, Wenbin Zeng. Fidelity-oriented fluorescence imaging probes for beta-galactosidase: From accurate diagnosis to precise treatment. Biotechnology advances. 2023 Nov;68:108244